OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

July 2nd 2020

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC

July 2nd 2020

Heinz-Josef Lenz, MD, FACP, discusses updated efficacy data from the phase 2 CheckMate-142 trial with nivolumab plus low-dose ipilimumab in metastatic colorectal cancer.

Dr. Catenacci on the Challenges of Developing Novel Therapies in Gastroesophageal Cancer

July 2nd 2020

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC

July 2nd 2020

Marwan Fakih, MD, discusses the safety profile of AMG 510 in KRAS G12C-mutated colorectal cancer.

Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

July 2nd 2020

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

Dr. Abid on the Impact of the COVID-19 Pandemic on Patients With Cancer

July 2nd 2020

Muhammad Bilal Abid, MD, MRCP, discusses the current coronavirus disease 2019 pandemic and its clinical impact on patients with cancer.

Dr. Landgren on the Clinical Benefit of Idecabtagene Vicleucel in R/R Myeloma

July 1st 2020

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

July 1st 2020

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

July 1st 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide in Prostate Cancer

July 1st 2020

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Dr. Schwartz on ​the Results of the Alliance A091401 Study in Metastatic Sarcoma

July 1st 2020

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

June 30th 2020

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL

June 30th 2020

Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.

Dr. Rana on the Prevalence of Pathogenic Variants in Prostate Cancer

June 30th 2020

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Dr. Costello on the Role of Daratumumab in Multiple Myeloma

June 30th 2020

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Dr. Munshi on the Current Landscape of CAR T-Cell Therapy in Multiple Myeloma

June 30th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma

June 30th 2020

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Dr. Weisel on the Safety Profile of Isa-KRd in High-Risk Multiple Myeloma

June 30th 2020

Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

NEXT PAGE
PREVIOUS PAGE